← Eichor
Condition: Geographic Atrophy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Geographic Atrophy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial
Phase N/A · 7 location(s) · Medical University of Vienna · NCT06351657Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geog
Phase 1/Phase 2 · 5 location(s) · AbbVie · NCT07160179Progression of Early Atrophic Lesions
Phase N/A · 1 location(s) · University of Utah · NCT05959005Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Mac
NA · 13 location(s) · VisionCare, Inc. · NCT04796545Phase 1 Study of C.001 in Retinal Degeneration
Phase 1 · 1 location(s) · Cellio Therapeutics Inc · NCT07594236A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic
Phase 1/Phase 2 · 1 location(s) · Bionic Sight LLC · NCT07158775A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Phase N/A · 65 location(s) · Astellas Pharma Global Development, Inc. · NCT06779773Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Phase 2 · 57 location(s) · ONL Therapeutics · NCT06659445A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy
Phase 1/Phase 2 · 3 location(s) · Theratocular Biotek Co. · NCT07668804A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
Phase 2 · 5 location(s) · Regenerative Patch Technologies, LLC · NCT06557460Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Phase N/A · 1 location(s) · Center for Eye Research Australia · NCT04739319Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT07502664A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secon
Phase 2 · 51 location(s) · Novartis Pharmaceuticals · NCT07441642Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
NA · 3 location(s) · Ospedale San Raffaele · NCT04847635Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Phase 1 · 8 location(s) · Regeneron Pharmaceuticals · NCT07230834A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geo
Phase 2 · 17 location(s) · Genentech, Inc. · NCT05626114Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
Phase N/A · 1 location(s) · AI-Spectral · NCT07446582An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geog
Phase 1/Phase 2 · 5 location(s) · Complement Therapeutics · NCT07392255A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se
Phase 2 · 104 location(s) · Janssen Research & Development, LLC · NCT06635148A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non
Phase 2 · 14 location(s) · Galimedix Therapeutics Inc · NCT06659549SGLT2 Inhibitors in Geographic Atrophy
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07174687A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and
Phase 2 · 78 location(s) · Apellis Pharmaceuticals, Inc. · NCT07215390Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Phase 1/Phase 2 · 3 location(s) · Eyestem Research Pvt. Ltd. · NCT06394232Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy As
Phase 1/Phase 2 · 2 location(s) · National Eye Institute (NEI) · NCT04339764A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Se
Phase 1/Phase 2 · 18 location(s) · Sanofi · NCT07215234A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due
Phase 1 · 19 location(s) · Astellas Institute for Regenerative Medicine · NCT03178149A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult
Phase 3 · 218 location(s) · Regeneron Pharmaceuticals · NCT06541704Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
Phase 2 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04292080Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NA · 5 location(s) · Okuvision GmbH · NCT07531927
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.